Oka, Kentaro

Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

Dizman, N., Meza, L., Bergerot, P., Alcantara, M., Dorff, T., Lyou, Y., Frankel, P., Cui, Y., Mira, V., Llamas, M., et al. (2022) · Nature Medicine

Cancer Immunotherapy and BiomarkersRenal cell carcinoma treatment

Cited by 515

Clostridium butyricum Modulates the Microbiome to Protect Intestinal Barrier Function in Mice with Antibiotic-Induced Dysbiosis

Hagihara, M., Kuroki, Y., Ariyoshi, T., Higashi, S., Fukuda, K., Yamashita, R., Matsumoto, A., Mori, T., Mimura, K., Yamaguchi, N., et al. (2020) · iScience

Gut microbiota and healthProbiotics and Fermented Foods

Cited by 162

Clostridium butyricum therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors

Tomita, Y., Goto, Y., Sakata, S., Imamura, K., Minemura, A., Oka, K., Hayashi, A., Jodai, T., Akaike, K., Anai, M., et al. (2022) · OncoImmunology

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 100

Oral microbiome alterations of healthy volunteers with proton pump inhibitor

Mishiro, T., Oka, K., Kuroki, Y., Takahashi, M., Tatsumi, K., Saitoh, T., Tobita, H., Ishimura, N., Sato, S., Ishihara, S., et al. (2018) · Journal of Gastroenterology and Hepatology

Oral microbiology and periodontitis researchGut microbiota and health

Cited by 96

Clostridium butyricum MIYAIRI 588-Induced Protectin D1 Has an Anti-inflammatory Effect on Antibiotic-Induced Intestinal Disorder

Ariyoshi, T., Hagihara, M., Eguchi, S., Fukuda, A., Iwasaki, K., Oka, K., Takahashi, M., Yamagishi, Y., & Mikamo, H. (2020) · Frontiers in Microbiology

Gut microbiota and healthProbiotics and Fermented Foods

Cited by 45